Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2021
Ofev (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases
4 March 2021 - Ofev is the first treatment available in Canada for chronic fibrosing interstitial lung diseases with a progressive ...
Posted by Michael Wonder on 03 Mar 2021
Health Canada approves Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinaemia
2 March 2021 - Approval is based on the Phase 3 ASPEN trial of Brukinsa compared to ibrutinib. ...
Posted by Michael Wonder on 02 Mar 2021
EMA and Health Canada publish clinical data used to support their authorisations of the Moderna COVID-19 vaccine
2 March 2021 - Openness and transparency are key to building confidence in COVID-19 vaccines. Today, EMA and Health Canada ...
Posted by Michael Wonder on 01 Mar 2021
Health Canada approves AstraZeneca's COVID-19 vaccine
26 February 2021 - Canada's regulator estimates vaccine's efficacy at 62.1 per cent. ...
Posted by Michael Wonder on 26 Feb 2021
Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache
25 February 2021 - The first and only anti-CGRP treatment with dual indications. ...
Posted by Michael Wonder on 26 Feb 2021
Medexus announces expanded availability of Gleolan in Canada
25 February 2021 - Medexus Pharmaceuticals announced today that it has initiated the commercial launch of Gleolan in Canada, which had ...
Posted by Michael Wonder on 25 Feb 2021
AbbVie’s Skyrizi for the treatment of moderate to severe plaque psoriasis now publicly reimbursed across Canada
24 February 2021 - Prince Edward Island lists Skyrizi on its Pharmacare Formulary effective 22 February 2021. ...
Posted by Michael Wonder on 24 Feb 2021
Bladder cancer drug shortage resolved with Health Canada approval
24 February 2021 - Verity-BCG bladder cancer treatment available for Canadian patients in the spring. ...
Posted by Michael Wonder on 24 Feb 2021
Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years
23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...
Posted by Michael Wonder on 21 Feb 2021
Ontario makes commitment to funding CF drugs after approval process completed
19 February 2021 - Ontario’s Health Minister Christine Elliott says life-saving cystic fibrosis medications that are inching their way through ...
Posted by Michael Wonder on 19 Feb 2021
Where is AstraZeneca’s vaccine? Health Canada says not yet ready to greenlight
18 February 2021 - Health Canada is not yet ready to make a decision about approving the COVID-19 vaccine from ...
Posted by Michael Wonder on 18 Feb 2021
Viatris launches Hulio (adalimumab biosimilar) in Canada
18 February 2021 - Viatris announced today that Health Canada has approved Hulio, and product is now available in Canada. ...
Posted by Michael Wonder on 18 Feb 2021
Fresenius Kabi Canada launches Idacio (adalimumab injection) a biosimilar to Humira (adalimumab) for the treatment of multiple chronic inflammatory conditions
18 February 2021 - Biosimilars offer patients access to affordable, meaningful medicines ...
Posted by Michael Wonder on 18 Feb 2021
HLS Therapeutics provides update on private and public payer reimbursement for Vascepa
16 February 2021 - Active negotiations have also begun with the pan-Canadian Pharmaceutical Alliance for reimbursement of Vascepa by publicly funded ...
Posted by Michael Wonder on 18 Feb 2021
Ultragenyx announces approval of Dojolvi (UX007/triheptanoin) in Canada for the treatment of long-chain fatty acid oxidation disorders in adults and children
17 February 2021 - First approved treatment for adult and paediatric patients with long-chain fatty acid oxidation disorders in Canada. ...